Effect of esomeprazole versus placebo on pulmonary exacerbations in cystic fibrosis
Effect of esomeprazole versus placebo on pulmonary exacerbations in cystic fibrosis
About this item
Full title
Author / Creator
Publisher
England: BioMed Central
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central
Subjects
More information
Scope and Contents
Contents
Gastro esophageal reflux (GER) is common in cystic fibrosis (CF) and may contribute to lung disease. Approximately 50% of patients with cystic fibrosis are being treated with proton pump inhibitors (PPIs).
In a randomized controlled study in adults, we compared treatment with esomeprazole 40 mg twice daily versus placebo in patients with CF and...
Alternative Titles
Full title
Effect of esomeprazole versus placebo on pulmonary exacerbations in cystic fibrosis
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3931289
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3931289
Other Identifiers
ISSN
1471-2466
E-ISSN
1471-2466
DOI
10.1186/1471-2466-14-21
